中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (1): 36-40.doi: 10.19401/j.cnki.1007-3639.2017.01.007

• 综述 • 上一篇    下一篇

三阴性乳腺癌靶向治疗最新进展

刘子梅 综述,沈 赞 审校   

  1. 上海交通大学附属第六人民医院肿瘤内科,上海 200233
  • 出版日期:2017-01-30 发布日期:2017-02-23
  • 通信作者: 沈 赞 E-mail:sshenzzan@vip.sina.com
  • 基金资助:
    国家自然科学基金面上项目(30872991)。

The latest developments in targeted therapy for triple-negative breast cancer

LIU Zimei, SHEN Zan   

  1. Department of Medical Oncology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China
  • Published:2017-01-30 Online:2017-02-23
  • Contact: SHEN Zan E-mail: sshenzzan@vip.sina.com

摘要: 三阴性乳腺癌(triple-negative breast cancer,TNBC)是一种特殊类型的乳腺癌,占乳腺癌总确诊的15%~20%。其雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)和人表皮生长因子受体(human epidermal growth factor receptor-2,HER-2)表达均阴性,具有独特的生物学特性和临床病理特征,肿瘤异质性很高,临床上具有复发高、转移早和预后差等特点。目前,临床上缺少有效的治疗手段。该综述介绍了TNBC的临床病理特征、分子亚型、几条重要的通路和靶点,以及目前各靶向药物临床试验研究进度,希望为今后TNBC的治疗提供新的临床思路。

关键词: 三阴性乳腺癌, 靶点, 治疗

Abstract: Triple-negative breast cancer (TNBC) is a special type of breast cancer, accounting for 15%-20% of all diagnosed breast cancer cases. Its estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2) expression is negative, with unique biological characteristics, clinicopathological features and tumor heterogeneity. Its clinical features include high incidence of relapse, early metastasis and poor prognosis. Currently, it lacks effective treatment. This review described the clinicopathological features of TNBC, its molecular subtypes, several important pathways and targets, as well as presented the progress in clinical studies of targeted drugs in the hope of generating new ideas for the treatment of TNBC in the future.

Key words: Triple-negative breast cancer, Target, Therapy